ClinicalTrials.Veeva

Menu

High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease

A

Anhui Medical University

Status

Enrolling

Conditions

Transcranial Direct Current Stimulation
Early Alzheimer's Disease
Functional Magnetic Resonance Imaging

Treatments

Other: HD-tDCS
Other: computer-based cognitive training
Other: Sham tDCS

Study type

Interventional

Funder types

Other

Identifiers

NCT04599764
AH med university2018913

Details and patient eligibility

About

To investigate the clinical effect neural mechanism of high-definition transcranial direct current stimulation combined with cognitive training on early AD

Full description

Upon meeting the inclusion criteria and providing informed consent, each participant will complete a series of cognitive assessments and tDCS at the hospital outpatient clinics or inpatient department. Participants were randomly allocated to anode tDCS group with cognitive training, anode tDCS group and the sham group. There are about 20 participants in each group. Participants were studied using a double-blind design. Study participants and all personnel responsible for the effects of the participants remained masked to allocated condition and allocation parameters. Only tDCS administrators had access to the randomization list; they had minimal contact with the participants, and no role in cognitive assessments. For the first 30 participants, allocation was decided by draw. For the subsequent 30 patients, allocation was according to computer generated random numbers. Each participant would be treated for 10 days in two weeks by HD-tDCS.

Before the tDCS, a series of cognitive assessments and neuropsychological tests were obtained by a trained investigator to assess baseline. Each assessment will involve a set of assessment tools, including Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Montreal Cognitive Assessment (MoCA) and associative memory as the primary outcome measure and various other tasks and questionnaires to measure cognition(DS, Stroop test, VFT, SDMT), memory (AVLT, AMT, working memory test), emotion(HAMA-17, HAMD-14, eye-tracking technolodgy), executive function(SST, WSCT, GDT) and stimulation tolerability. All the tests are conducted in two days. The participants had receiving a magnetic resonance imaging scan in multi-modalities, and electroencephalography (EEG) record.

Evaluations were conducted one week after treatment and at the end of two weeks of treatment, as well as the Global Index of Safety to assess adverse events of the stimulation. Participants were instructed to focus their answers on the past 7/14 days. The participants had also receiving a battery measure of neuropsychological tests, magnetic resonance imaging scan in multi-modalities, and EEG record. All tests were instructed to finished within 24 hours after the last stimulation. One month and three months after the last stimulation, participants were interviewed to obtain the same assessment as before. They were instructed to focus their answers on the past months.

Enrollment

60 estimated patients

Sex

All

Ages

50 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria.
  • Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia
  • CDR score ≤ 2
  • Subject under treatment by IAChE for at least 3 months.
  • psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months

Exclusion criteria

  • CDR > 2
  • Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).
  • History of head injury,stroke,or other neurologic disease.
  • Organic brain defects on T1 or T2 images.
  • History of seizures or unexplained loss of consciousness.
  • Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.
  • Family history of medication refractory epilepsy.
  • History of substance abuse within the last 6 months.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

60 participants in 3 patient groups

Sham-Anode tDCS&Cognitive training
Sham Comparator group
Description:
Participants will receive Cognitive training+Sham tDCS daily for two weeks
Treatment:
Other: Sham tDCS
Other: computer-based cognitive training
Anodal tDCS with Cognitive training
Active Comparator group
Description:
Participants will receive anoale tDCS daily and cognitive training for two weeks
Treatment:
Other: computer-based cognitive training
Other: HD-tDCS
Anodal tDCS without Cognitive training
Active Comparator group
Description:
Participants will receive anoale tDCS daily without cognitive training for two weeks
Treatment:
Other: HD-tDCS

Trial contacts and locations

1

Loading...

Central trial contact

Kai Wang, PhD; Xingqi Wu, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems